Intellia Therapeutics Inc.

Sticking with genetic targets validated by Alnylam and Ionis gave Intellia confidence to take CRISPR in vivo

An ex vivo gene knockout approach helped the company become first to market with a gene editing therapy

Founding CEOs of gene editing companies discuss their pipeline strategies and lessons learned

Genetic therapies compete in the same indications, as degraders come of age

Week’s management moves include new venture partners at Frazier and updates from Beigene, Intellia and more

Also in BioCentury’s weekly Venture Report: Formela stepping back from Atlas’ new fund, nine-digit rounds for Nuvig and Maze, and more

Also in BioCentury’s latest Clinical Report, CRISPR and RNAi face off in ATTR data from Intellia, Alnylam; plus dermatology setbacks for Incyte

Clinical Report: Celldex advances in a second urticaria type, Eledon’s mAb helps Type I diabetes patients become insulin-independent, and more

What Forbion’s $2.2B raise says about the state of venture, NIH’s Daniel Reich on MS and RNA-editing oligo data from Wave 

In first human RNA-editing data, Wave reports positive results from WVE-006 in alpha-1 antitrypsin deficiency